Search
Acipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.
Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. … Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties.
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalor water restrictions. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
Argatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalThe American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary … Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexBuserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalBuserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalGuselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. … Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Ecamsule
go.drugbank.com/drugs/DB09534ApprovedEcamsule is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability. … Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal.
Categories: Compounds used in a research, industrial, or household settingMetixene
go.drugbank.com/drugs/DB00340ApprovedMetixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Octamoxin
go.drugbank.com/drugs/DB09249ApprovedWithdrawnOctamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class. … This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNialamide
go.drugbank.com/drugs/DB04820ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome